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Abstract
In hormone receptor-positive breast cancers, most tumors in the early stages of development depend on the activity of the
estrogen receptor and its ligand, estradiol. Anti-estrogens, such as tamoxifen, have been used as the first line of therapy for
over three decades due to the fact that they elicit cell cycle arrest. Unfortunately, after an initial period, most cells become
resistant to hormonal therapy. Peptidylprolyl isomerase 1 (Pin1), a protein overexpressed in many tumor types including
breast, has been demonstrated to modulate ERalpha activity and is involved in resistance to hormonal therapy. Here we
show a new mechanism through which CDK2 drives an ERalpha-Pin1 interaction under hormone- and growth factor-free
conditions. The PI3K/AKT pathway is necessary to activate CDK2, which phosphorylates ERalphaSer294, and mediates the
binding between Pin1 and ERalpha. Site-directed mutagenesis demonstrated that ERalphaSer294 is essential for Pin1-
ERalpha interaction and modulates ERalpha phosphorylation on Ser118 and Ser167, dimerization and activity. These results
open up new drug treatment opportunities for breast cancer patients who are resistant to anti-estrogen therapy.
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Introduction
In the normal mammary gland, estrogen receptor alpha
(ERalpha) and its ligand, estradiol (E2), primarily control the
ductal outgrowth and side branching that occur during pregnancy
and the menstrual cycle [1,2]. Only 15–25% of mammary
epithelial cells express ERalpha. These cells appear to be in a
non-proliferative state and act to stimulate the growth of
surrounding ERalpha-negative cells in response to estrogen. By
contrast, the majority (70%–80%) of primary breast tumors
express high levels of ERalpha and the growth of these tumors is
estrogen-regulated [3]. As a consequence, inhibition of ERalpha
activity by hormonal therapies reduces recurrence and improves
clinical outcomes in breast cancer patients [4,5].
ERalpha belongs to the superfamily of steroid nuclear receptor
transcription factors and shares four main functional domains with
other nuclear hormone-responsive receptors: the N-terminal
transcriptional activation function (AF-1) domain, DNA-binding
domain (DBD), hinge region and ligand-binding domain (LBD)
(AF-2). When estradiol binds to the AF-2 domain, it induces
structural changes that facilitate ERalpha dimerization, nuclear
translocation and the binding of DNA to regulate gene transcrip-
tion [6]. The AF-1 domain is regulated by growth factor receptor
signaling, including epidermal growth factor receptor (EGFR),
HER2 and insulin-like growth factor receptor (IGF1-R) [7]. The
DBD and LBD domains are structurally ordered with a globular
profile when expressed independently [8]. The three-dimensional
native-fold structure of the N terminal and hinge domains has not
yet been resolved as they are intrinsically disordered regions [9].
The hinge region, although initially characterized as merely a
flexible connection between the DBD and LBD regions, has
recently been discovered to have a more complex function.
Indeed, it comprises the nuclear translocation signal and includes
estrogen-independent regulatory sequences: selective mutation
studies showed that the binding of ERalpha to c-Jun and Sp-1
transcription factors requires an intact hinge domain [10]. The
complexity of this domain is further increased since its functional
transactivation is mediated by many posttranslational modifica-
tions such as methylation, acetylation, sumoylation and phosphor-
ylation [11–13]. In particular, the hinge region contains Ser294, a
canonical Ser/Thr-Pro motif. This motif has been discovered to
have a pivotal function in the regulation of protein activity.
The Ser/Thr-Pro motifs exist in two distinct conformations: cis
and trans [14]. Significantly, phosphorylation on Ser/Thr-Pro
motifs has a steric hindrance function that further restrains the
already slow cis/trans prolyl isomerization of peptide bonds [15].
Peptidylprolyl isomerase 1 (Pin1) is a unique member of one out of
three protein families, the parvulins, which interacts with and
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isomerizes phosphorylated Ser/Thr-Pro motifs. The final result of
the isomerization activity of Pin1 is a conformational change that
can alter protein function, localization and/or stability [16]. For
the aforementioned reasons, Pin1 has multiple roles in tumori-
genesis [17] with important implications in breast cancer
development and resistance to hormonal therapy [18–22]. With
regards to ERalpha, it has recently been reported that Pin1 can
directly and indirectly regulate its activity. Pin1 can stimulate the
function of ERalpha by promoting SRC-3 coactivator activity and
turnover [23] or by promoting CDK2-dependent SMRT core-
pressor protein degradation [24]. Finally, it has been demonstrated
that Pin1 can directly interact with FBS- or estrogen-stimulated
ERalpha, regulating its transcriptional activity through Ser118 [4].
ERalphaSer118, Ser167, and to a lesser extent, Ser104/106, are
the main residues phosphorylated in the AF-1 domain [25–29]
and have a central role in the regulation of transcriptional activity
of the receptor [25].
In the present study, we show that Pin1 regulates the functions
of ERalpha under basal conditions through its interaction with
Ser294. We demonstrate that a mutation of Ser294 reduces the
levels of Ser118 and Ser167 phosphorylation with important
implications for ERalpha dimerization and activation. Finally, we
propose a new working model for Pin1 and ERalpha and suggest a
novel pathway that can be inhibited to overcome resistance to
hormonal therapy.
Materials and Methods
Cells culture conditions
MCF7 breast cancer cell lines were purchased from American
Type Culture Collection (ATCC, Rochville, MD, USA), 293FT
from Invitrogen (Invitrogen Corp, Carlsbad, CA, USA). Cells were
grown at 37uC, in a 5% CO2/95% atmosphere. Hormone-free
medium was prepared with phenol red–free EMEM with
2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids,
50 units/mL penicillin, 50 mg/mL streptomycin, and 3% char-
coal-stripped FBS.
Reagents
Antibodies were purchased from: Pin1 (600-401-A20), 6XHis
(600-401-382) from Rockland Immunochemicals, Gilbertsville,
PA, USA; ERalpha (sc-8002), ERalphaS-118 (sc-101675), p-AKT
(sc-7985R), from Santa Cruz Biotechnology, Santa Cruz, CA,
USA;
ERalphaS-167 (31478), from ABCAM Cambridge, MA, USA;
a-tubulin (T-6074) from Sigma Inc., St Louis, MO, USA; AKT
(9272), MAPK (9102), p-MAPK (9101) from Cell Signaling,
Beverly, MA, USA. Kinase inhibitors were purchased from:
flavopiridol (F3055) from Sigma Inc., St Louis, MO; AG825
(1555) and U0126 (1144) from Tocris Bioscience, Ellisville,
Missouri 63021, USA; LY294002 (9901) from Cell Signaling,
Beverly, MA, USA. Estradiol was purchased from Sigma Inc., St
Louis, MO, USA
Plasmids
shRNA plasmids Pin1 (SHCLNG-NM_006221), CDK1
(SHCLNG-NM_001786), CDK2 (SHCLNG-NM_001798) and
CDK4 (SHCLNG-NM_000075) were obtained from Sigma Inc.,
St Louis, MO, USA. Scrambled shRNA (17920), psPAX2
packaging plasmid (12260) and pMDG.2 envelope plasmid
(12259) were obtained from Addgene Inc, Cambridge, MA, USA.
For GST pull-down experiments, the IMAGE: 3941595 clone
was utilized to amplify the Pin1 human gene with the oligonu-
cleotide primers PIN1-BamHIF GCGGATCCGCGGCAG-
GAGGGAAGATGG at the 59 end and PIN1-EcoRIR
GCGAATTCCTGGGCTCCCCACCCTCAC at the 39 end
with BamHI and EcoRI adaptor sequences, respectively. The
PCR generated products were ligated in the pGEX-2T plasmid for
the prokaryotic expression vector (Stratagene Inc., La Jolla CA,
USA).
ERalpha- His-AB, His-CD and His-EF plasmids were derived
from VP16-ERalpha (ADDGENE:11351) following amplification
with primers: AB-BamHI-F ATG GAT CCA CCA TGA CCA
TGA CCC TCC-39, AB-EcoRI-Rev 59-ATG AAT TCT CCT
TGG CAG ATT CCA TAG-39, CD-BamHI-F 59-ATG GAT
CCA CCA TGG CCA AGG AGA CTC GCT ACT GTG-39,
CD-EcoRI-Rev 59-ATG AAT TCT TCT TAG AGC GTT TGA
TCA TG-39. EF-BamHI-F 59-ATG GAT CCA CCA TGT CTA
AGA AGA ACA GCC TGG CC-39, EF-EcoRI-Rev 59-ATG
AAT TCC AGA CCG TGG CAG GGA AAC-39. After BamHI/
EcoRI double digestion, fragments were ligated in pcDNA6 His/
Myc vector. ERalpha-His-CDSer294Ala was generated by site-
directed mutagenesis with the QuickChange mutagenesis kit
(Stratagene, La Jolla, CA, USA).
To obtain pM-GAL4DBD-ERalpha, we digested VP16-ERal-
pha with EcoRI. The pM destination vector was digested with
BamHI and XbaI. The ERalpha fragment and pM vector ends
were filled with Klenow polymerase and ligated.
ERalphaSer294Ala was generated by site-directed mutagenesis
with the QuickChange mutagenesis kit (Stratagene, La Jolla, CA,
USA) and confirmed by direct sequencing. VP16-ERalpha was
used as the template for the mutagenesis. The primers used were:
ERS294A-f1 59-GCTGCCAACCTTTGGCCAGCCCCGCT-
CATGATCAAACGC-39 and ERS294A-r1 59-GCGTTTGAT-
CATGAGCGGGGCTGGCCAAAGGTTGGCAGC-39
All the plasmids were sequence verified.
Lentiviral production
To generate knock down cells, lentiviral particles were produced
as described (http://www.broadinstitute.org/genome_bio/trc/
publicProtocols.html) and Rizzolio et al. [30].
Real-time PCR
Total RNA was prepared from tissues using the RNA extraction
kit RNAeasy (Qiagen Inc, Valencia, CA, USA). One mg of total
RNA was reverse transcribed in a 20 ml reaction using M-MLV
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primers to
amplify CTSD, TFF1, GAPDH were as follows: CTSD-f 59-GCT
GGG AGG CAA AGG CTA CAA-39 CTSD-r 59-TCC TGC
TCT GGG ACT CTC CT-39, TFF1-f 59-CCC TGG TGC TTC
TAT CCT AAT A-39, TFF1-r 59-AGA AGC GTG TCT GAG
GTG TCC-39, GAPDH-f 5-GAA GGT GAA GGT CGG AGT-
39, GAPDH-r 5-CAT GGG TGG AAT CAT ATT GGA-39.
Quantitative Real-Time PCR (qRT-PCR) was performed with
SYBR Green PCR Master Mix (Roche Diagnostic, Basel,
Switzerland) in a LightCyclerH 480 Real-Time PCR System
instrument (Roche Diagnostic, Basel, Switzerland). Samples were
run in triplicates and the efficiency of each primer was calculated
utilizing an internal standard control [31][32]. All values were
normalized for GAPDH.
GST pull-down assay
GST and GST-Pin1 proteins were produced in BL21 bacteria
cells. Cells were grown to mid log phase and then induced to
express protein by adding 0.25 mM of isopropyl-1-thio-b-D-
galactopyranoside (IPTG, Roche Applied Science, Indianapolis,
IN, USA). The cultures were shaken for 4 h; bacteria were then
pelleted and resuspended in NENT buffer (20 mM Tris (pH 8),
Pin1 Regulates ERa
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100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA),
0.5% NP-40). Cell suspensions were sonicated and pelleted so that
the supernatant could be collected. The supernatant was
incubated with glutathione agarose beads (Sigma Inc., St Louis,
MO, USA) overnight at 4uC. The agarose beads were pelleted and
washed three times in NENT buffer. The GST protein was
analyzed by electrophoresis gel and blue coomassie staining. 1 mg
of protein was pulled down with 10 ug of GST or GST-Pin1.
Co-immunoprecipitation assay
Sub-confluent MCF7 cells were harvested and proteins were
prepared as follows: the cell pellet was resuspended in lysis buffer
(20 mM Tris HCl pH 8, 137 mM NaCl, 10% glycerol, 1% NP40,
2 mM EDTA). 1 mg of proteins was immunoprecipitated,
utilizing 4 mg of Pin1, ERalpha antibody or mouse IgG overnight
at 4uC. The immunoprecipitated protein complex was collected
with agarose protein A/G beads (Pierce) for 3 h at 4uC. After
washing, the protein immunocomplex was run on SDS-PAGE
followed by immunoblot analyses to detect Pin1 or ERalpha
proteins.
In vitro kinase assays
GST-D WT or mutant constructs were purified from E. Coli,
1 mg of recombinant protein incubated with 100 U of CDK2/
CycA2, CDK4/CycD1, CDK6/CycD1 (SignalChem, Richmond,
Canada) in the kinase reaction buffer (40 mM Tris HCl, 20 mM
MgCl2, 0.1 mg/ml BSA, 0.2 mM, ATP, 2 mM DTT) for
30 minutes at RT. The reaction was analyzed with the Kinase
Glo luminescence assay (Promega, Wisconsin, USA) according to
the manufacturer’s protocol.
Dimerization assay
293FT cells were seeded in 96 multiplate wells at 26104 cells/
well and grown in hormone-free medium. After three days, cells
were transfected (Fugene HD, Roche Applied Science, Indianap-
olis, IN, USA) with 300 ng of VP16ERalpha and pM-GAL4DBD-
ERalpha wild-type or Ser294Ala mutant, 300 ng of GAL4-LUC-
pGL2Basic (Promega E1641) and 50 ng of renilla plasmid
(Promega, E2241). After 24 hours, cells were treated with
10 nM of 17-b-estradiol for 12 hours. The luminescence of each
sample was measured in a single tube luminometer (Berthold
Technologies, GmbH & CO, Germany) with the Dual-Luciferase
Reporter Assay System (Promega, E1910). Each transfection was
performed three times in order to overcome the variability
inherent in the experiment.
Statistical analysis
Statistical analyses were performed using GraphPad software by
applying unpaired Student’s t-test. Quantification of western blot
was carried out with Adobe Photoshop.
Results
Pin1 interacts with ERalpha under basal conditions
Previous studies demonstrated that Pin1 indirectly controls
ERalpha activity [23,24] or via direct binding to phosphorylated
Ser118 under hormone or growth factor stimulation [4]. To
further clarify the role of Pin1 in the regulation of ERalpha
activity, we immunoprecipitated Pin1 in the presence or absence
of 17-b-estradiol in MCF7 cells (Fig. 1A). Pin1 kd cells (Fig. 1B)
and IgG were used as a negative control. We demonstrated that,
under both conditions, Pin1 forms a macromolecular complex
with ERalpha in vivo. To understand which mechanism is involved
in the interaction between Pin1 and ERalpha under basal
conditions, we then decided to carry out all experiments in the
absence of FBS and estradiol unless indicated.
Pin1 is a short protein that contains two known functional
domains, a WW interacting domain (amino acids 6–37) and a
PPIase domain (amino acids 54–163). Total cellular lysate was
incubated with GST, GST-Pin1 protein, GST-WW and GST-PP
domains (Fig. 1C). GST pull-down assays confirmed that both the
WW domain and PPIase domain are critical for ERalpha
interaction.
The CD domain in ERalpha is responsible for Pin1 binding
To clarify which ERalpha domain is involved in the binding of
Pin1, ERalpha protein was split into three regions (domains A/B,
CD and EF) (Fig. 2A) and fused with a C-terminal Histidine tag for
further analysis. Plasmids were transfected in 293FT cells and total
cellular lysate was pulled down with GST and GST-Pin1 proteins
(Fig. 2B). Using a 66-His antibody, we were able to demonstrate
that only CD peptide interacts with GST-Pin1 but not GST. As
Pin1 is a peptidyl-prolyl-isomerase that specifically recognizes and
isomerizes phosphorylated Ser/Thr-Pro motifs, we explored
putative sites in the CD region that match the consensus motif.
We found that Ser294 was a unique Ser-Pro site located in the D
domain (Fig. 2A). To confirm that Ser294 is responsible for the
binding between ERalpha and Pin1, a Ser294Ala mutation (MT)
was introduced by site-directed mutagenesis. 293FT cells were
transfected with CD wild-type and mutant domains. GST-pull
Figure 1. Pin1 associates with ERalpha both in vitro and in vivo.
A) Serum-starved cells were treated with estradiol (E2) or ethanol for
459. Cells were harvested and pellets immunoprecipitated with anti-
Pin1, and analyzed by Western blot with anti-ERalpha antibody. Pin1 kd
cells or IgG were used as a negative control. B) MCF7 cells were
transfected with shRNA scramble (SCR) or shRNA Pin1 (kd1 and kd2),
and Pin1 protein level was detected by immunoblotting. GAPDH was
used as the load control. Quantification represents the ratio between
the Pin1 and GAPDH proteins and normalized to scrambled cells. C)
GST, GST-Pin1, GST-WW or GST-PPIase fusion proteins were incubated
with ERalpha-positive MCF7 cell lysates and the bound proteins were
analyzed by immunoblotting with an ERalpha antibody.
doi:10.1371/journal.pone.0055355.g001
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down experiments showed that mutation in the CD peptide
greatly reduced the ability of the ERalpha protein to bind to Pin1,
(Fig. 2C) confirming Ser294 as the Pin1 binding site.
CDK2 interacts with and phosphorylates the CD peptide
to generate the Pin1-binding site
Since Pin1 activity requires prior phosphorylation of its target
site and the Ser/Thr-Pro motif is the minimal consensus sequence
recognized by Cyclin Dependent Kinases (CDKs) [33], we
investigated whether CDK-mediated phosphorylation of Ser294
elicits Pin1 binding. For this purpose, shRNA CDK1, CDK2 and
CDK4 were stably expressed in 293FT cells (Fig. 3A) and
transfected with the ERalpha CD domain. GST-Pin1 was used as
a bait protein to immunoprecipitate the CD domain. After pull
down, we observed a reduced amount of the CD domain in 293FT
cells expressing shRNA CDK2 compared to shRNA CDK1 or
CDK4 proteins (Fig. 3B). To confirm this result, a kinase assay was
performed on WT and Ser294Ala D domains and used as a
substrate for the active form of CDK2/CycA, CDK4/CycD1 and
CDK6/CycD1 kinase complexes. Detection of kinase activity was
performed using Kinase Glo luminescence assay. CDK2 efficiently
phosphorylates the wild-type D domain and to a lesser extent the
Ser294Ala D domain. CDK4 and CDK6 show a very weak
activity on the D domain. The result confirms that CDK2 can
bind and phosphorylate ERalpha in the D domain and facilitates
Pin1 binding by generating a phospho-Ser-Pro site (Fig. 3C).
In order to further demonstrate the involvement of the CDK
pathway in Pin1-ERalpha binding, we decided to use flavopiridol
(FLV), a potent CDKs-inhibitor. MCF7 cells cultured in phenol-
red-free and hormone-free medium were treated for 16 hours with
0.25-0.125 mM concentrations of FLV. As expected, inhibition of
CDK activity blocked Pin1 binding on ERalpha (Fig. 3D).
Ser294 is involved in Ser118 and Ser167 phosphorylation
and participates in ERalpha dimerization
Phosphorylation of ERalpha on serine 118 and 167 is required
for the full activity of protein function [25]. Both residues are
located within the N-terminal region (AF-1), which is known to
promote transcription in a ligand-independent manner. However,
phosphorylation of these serines is enhanced in response to ligand
binding in the AF-2 domain. In order to examine the significance
of Ser294 in relation to ERalpha phosphorylation in vivo, a full-
length ERalpha expression plasmid bearing the mutation Ser294-
Ala was generated. 293FT cells were co-transfected with ERalpha
WT or Ser294Ala and GFP plasmid as controls. Two days before
treatment, cells were grown in phenol-red-free medium containing
3% charcoal-stripped FBS. After 45 min of E2 treatment, cellular
pellets were collected and lysed for Western blot analysis. We
could note that phosphorylation on Ser118 and Ser167, both
implicated in ERalpha transcriptional activation, was reduced in
cells transfected with the Ser294Ala ERalpha plasmid. The
Ser294Ala is located in the D domain, a flexible region that lies
between two distinct dimerization interfaces in the DBD and LBD
regions [34]. To investigate the involvement of Ser294 in E2-
dependent ERalpha dimerization and transcriptional activation, a
mammalian two-hybrid assay was used. ERalpha- WT and
Ser294Ala constructs were cloned in pGAL4 (DBD) and pVP16
to generate hybrid fusion proteins and transfected as homodimers
in 293FT cells. Transfected cells were treated with E2 or a vehicle
for 16 h. We observed a statistically significant reduction of
ERalphaSer294Ala activity compared to wild-type ERalpha
(Fig. 4B). These experiments show that phosphorylation of
Ser294 is required for proper phosphorylation of ERalpha
following hormone-induced stimulation.
To confirm that Pin1 modifies ERalpha activity, we carried out
a real-time PCR (qRT-PCR) on two well-known estrogen-induced
genes (CTSD and TFF1) in Pin1 kd MCF7 cells treated with E2
for 6 h (Fig. 4c). We were able to detect a reduction in mRNA
levels for both the CTSD and TFF1 genes.
PI3K/AKT is involved in the Pin1-ERalpha interaction
ERalpha is regulated by multiple signaling pathways including
the PI3K/AKT pathway and the extracellular-regulated kinase
pathway (MAPK). Neither pathway excludes the other, and they
can activate ERalpha in a ligand-dependent or -independent
manner [25]. To investigate which pathways stimulate the Pin1-
ERalpha interaction, we treated the MCF7 cells with drug
Figure 2. ERalpha CD domain interacts with Pin1. A) Schematic
representation of ERalpha domains, showing the predicted prolyl
isomerase sites (Ser/Thr-Pro). B) ERalpha cDNA was split into three
different domains (AB, CD, EF) and tagged with histidine. GST or GST-
Pin1 pull-down assay was performed in 293FT cells and analyzed by
Western blot with anti-66His antibody. C) Site-directed mutagenesis
was performed to replace Serine 294 with Alanine on the ERalphaCD
domain. Plasmids with wild-type (w) or mutant (m) CD His-tagged
domain were transfected in 293FT cells and pulled down with GST-Pin1
protein. Anti-His antibody was used in Western blots to detect the
interaction.
doi:10.1371/journal.pone.0055355.g002
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inhibitors of PI3K (LY294002), Her2 (AG825) and Mek1/2
(U0126). We performed the experiments in the absence or
presence of FBS, with similar results. GST-pull down with Pin1
fusion protein performed on MCF7 cellular lysates showed a
marked reduction in Pin1/ERalpha binding in the presence of the
PI3K/AKT inhibitor LY294002 (Fig. 5A and data not shown).
These results suggest a contribution of the PI3K/AKT pathway
and CDK2 activity on EralphaSer294. Differently, Her2 and
Mek1/2 inhibitors did not affect Pin1 binding, excluding their
involvement in this mechanism (data not shown).
Discussion
Evaluation of the ERalpha status is an essential component in
the pathological classification of breast cancers and determines the
success of endocrine therapies [35]. Endocrine agents are currently
used as first line therapy for ERalpha-positive breast cancers [36].
These treatments target the ERalpha pathway by blocking the
receptor’s activity or starving the tumor of estrogens.
A number of studies suggest that the benefit of endocrine
therapy is proportional to the level of ERalpha expression [37–39]
and therefore further characterization of the factors that determine
the precise levels of ERalpha is essential. However, although
beneficial, resistance to hormonal therapy occurs in 50% of
patients and it remains crucial to determine the underlying
molecular mechanism [40]. Recent data support the concept that
Pin1 is implicated in the acquired resistance to tamoxifen
[4,18,41], a drug that has been used in the clinical setting for
more than 30 years [7]. In particular, Pin1 is involved in the
overexpression of the HER-2 receptor [18] and controls the
activity of ERalpha by regulating the stability of its cofactors,
SRC-3 [23] and SMRT [24]. Furthermore, it has been
demonstrated that under FBS or estradiol conditions, Pin1 can
regulate ERalpha activity through interaction with phospho-
Ser118 [4]. The authors suggested that when Ser118 is
phosphorylated, the ERalpha N-terminus is preferentially restrict-
ed in the cis conformation. After Pin1 binding, the AF1 domain is
switched to the trans conformation by promoting a slight local
structural change [4].
Here we report that under basal conditions, ERalpha Ser294 is
the target of Pin1. We demonstrated by GST pulldown and
coimmunoprecipitation assays on MCF7 cell extracts that Pin1
Figure 3. CDK2 allows ERalphaSer294 and Pin1 interaction. A) 293FT cells were infected with 1 MOI of specific CDKs or Scrambled shRNA
lentivirus as indicated. B) 293FT cells knocked down for CDK1, CDK2 and CDK4 genes were transfected with ERalphaCD domain and pulled down with
GST-Pin1. Quantification represents the ratio between the pull down and total ERalpha protein and normalized to scrambled cells. C) Kinase assay
was done on wild-type or mutant ERalphaD domains. The D domain was incubated with activated CDK/cyclin complexes as indicated and the kinase
activity was measured in Relative Luciferase Unit/Second (RLU/s). Data shown represent average values 6 S.D. n= 3. In the lower panel, the GST-D
domain and cyclin/CDKs complexes loading controls. D) Cells were treated with flavopiridol at different drug concentrations and pulled down with
GST or GST-Pin1. The level of phosphorylation of pRb was used to control the efficacy of flavopiridol.
doi:10.1371/journal.pone.0055355.g003
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interacts with ERalpha and this interaction was reduced when
serine 294 was mutated to alanine.
The hinge region is a relatively short domain spanning 51
amino acids (263–314), and with several important functions in
ERalpha regulation. Complete deletion of the hinge region
impairs ligand-induced downregulation of the receptor [10,42].
In the N-terminal region (253–282 aa) overlapping the DNA
binding domain resides the ERalpha nuclear localization sequence
(NLS) that includes a protein-protein interaction sequence (267–
275 aa) for c-Jun transcriptional factor [10]. Moreover, sumoyla-
tion of lysines 302/303 promotes ligand-induced polyubiquitina-
tion, which is required for receptor turnover [43]. The localization
of Ser294 in the hinge region near the DBD domain suggests a
role [13,44] in DNA binding and/or dimerization of ERalpha.
Using a two-hybrid assay, we demonstrated that Ser294 is
effectively involved in dimerization and consequently in ERalpha
activation. After estradiol stimulation, a significant reduction in
transcriptional activity was detected in cells transfected with
ERalpha mutant, suggesting that a Ser294Ala mutation impairs
dimerization.
On the basis of results in the literature [4] and our own data
[45], we proposed a working model in which Pin1 regulates
ERalpha in two different steps: under basal conditions, there is a
first event mediated by CDK2 phosphorylation that takes place on
Ser294. This step is required for Pin1 binding and subsequent
phosphorylation of Ser118 and Ser167. In the second step, growth
Figure 4. Ser294 is involved in Ser118 and Ser167 phosphor-
ylation and participates in ERalpha dimerization. A) 293FT cells
were transfected with ERalpha wild-type (W) and Ser294Ala plasmid
constructs. After 17-b-estradiol treatment, cell lysates were immuno-
blotted and probed with ERalpha Ser118 and Ser167 phospho-specific
antibodies. The GFP plasmid was utilized as the internal control of
transfection. Quantification represents the ratio between the phos-
phorylated and total ERalpha protein and normalized to WT ERalpha
protein. B) The pGL2 Luciferase reporter construct was transfected into
293FT cells together with either GAL4/VP16 ERalpha WT or GAL4/VP16
ERalpha Ser294Ala plasmids. The values represent the luciferase activity
normalized to Renilla. Transfected cells were treated with 10 nM 17-b-
estradiol to stimulate ERalpha dimerization. The data represent the
average of three different experiments. Error bars represent 6SD. p-
value,** 0.01 C) Real-time PCR analysis of CTSD and TFF1 ERalpha-
target genes in scrambled and Pin1 kd cells. The values are normalized
to the GAPDH gene. Data represent the average of three replicates.
Error bars represent 6SD. p-value,* 0.05 or ** 0.01.
doi:10.1371/journal.pone.0055355.g004
Figure 5. The PI3K-CDK pathway is responsible for interaction
between Pin1 and ERalpha. A) MCF7 cells were grown in normal
serum and treated with different micro Molar concentration of
LY294002 or flavopiridol drugs for 16 hours. Total protein lysates were
pulled down (PD) with GST-Pin1. AKT was used as the control of
LY294002 treatment. B) Pin1 and ERalpha working model under basal
and estradiol-stimulated conditions. See text for details.
doi:10.1371/journal.pone.0055355.g005
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factor stimulation promotes Pin1 recruitment to ERalpha at
phosphoSer118, modulating AF-1 functional activity (Fig. 5B).
Since the proper phosphorylation levels of Ser118 and Ser167
have been associated with a clinical response of patients treated
with tamoxifen [46–48], it appears that Pin1 has a critical role in
this mechanism.
Although Ser294 has a proven role in the activity of ERalpha,
there is a lack of information regarding the pathway involved in
Ser294 phosphorylation and its functional significance. Serines
residues located in the N-terminal domain (Ser104/106, Ser118,
Ser167) and in the Hinge region (Ser294) match the consensus
sequence recognized by families of Serine/Threonine proline
directed kinases, including cyclin-dependent kinases. ERalpha
transcriptional activity is virtually abolished under conditions
where CDK2 activity is suppressed by the kinase inhibitor p27 or
by a dominant negative CDK2 mutant, regardless the presence or
absence of hormones [49]. Thus it appears that CDK2 is a limiting
cofactor in the regulation of ERalpha-dependent transcription. We
demonstrated that Ser294 amino acid represents a new target for
CDK2, and its phosphorylation is required for Pin1 binding, a
mechanism elicited by the PI3K pathway. Currently, the detailed
signaling pathway that sustains the Pin1-ERalpha interaction
remains obscure although there are different experimental models,
which have demonstrated a link between PI3K and CDK2 activity
in a different tissue context. The PI3K pathway promotes Thr-160
phosphorylation in the CDK2 activating site [50–52]. Of note,
Pin1 can stabilize the AKT protein [52], suggesting a multiple
level mechanism in which Pin1 controls the PI3K/AKT pathway
[53]. Further studies will be done to clarify the PI3K signaling
cascade in CDK2/ERalpha regulation in breast cancer.
Overall, our results suggest a new pathway that involves PI3K/
AKT, CDK2 and Pin1 and open up new opportunities for treating
ERalpha-positive breast cancer patients who are resistant to
hormonal therapy.
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